Xeris Biopharma Holdings (XERS) closed at $10.20 on October 23, 2026, down 6.1% from the previous close, on volume of 2,275,109 shares (30-day average 2,991,282).
Data as of October 23, 2026.
23-Oct-2026
Business Wire (Thu, 22-Oct 8:00 AM ET)
Business Wire (Thu, 15-Oct 8:00 AM ET)
Xeris uses inducement equity plan to hire 60 employees, granting 352,170 shares in options and RSUs
Market Chameleon (Mon, 5-Oct 7:49 AM ET)
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Fri, 2-Oct 5:00 PM ET)
Business Wire (Wed, 9-Sep 8:30 AM ET)
Xeris Announces Details for XP-8121 Program Overview Webinar
Business Wire (Wed, 26-Aug 7:30 AM ET)
Market Chameleon (Thu, 6-Aug 4:22 AM ET)
Xeris Biopharma Reports Second Quarter 2026 Financial Results
Business Wire (Thu, 6-Aug 7:00 AM ET)
Market Chameleon (Thu, 7-May 3:50 AM ET)
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Xeris Biopharma Holdings trades on the NASDAQ stock market under the symbol XERS.
As of October 23, 2026, XERS stock price declined to $10.20 with 2,275,109 million shares trading.
XERS has a beta of 1.66, meaning it tends to be more sensitive to market movements. XERS has a correlation of 0.15 to the broad based SPY ETF.
XERS has a market cap of $1.86 billion. This is considered a Small Cap stock.
Last quarter Xeris Biopharma Holdings reported $92 million in Revenue and $.00 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, XERS traded as high as $11.42 and as low as $1.46.
The top ETF exchange traded funds that XERS belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.
XERS has underperformed the market in the last year with a price return of +11.7% while the SPY ETF gained +14.3%. However, in the short term, XERS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +21.3% vs +3.2% return in SPY. But in the last 2 weeks, XERS shares have been beat by the market, returning -2.7% compared to an SPY return of -2.4%.
XERS support price is $10.44 and resistance is $11.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XERS shares will trade within this expected range on the day.
